Inhibition of nonsense mediated decay pathways

Patent metadata

Field	Value
Publication number	US-2016243218-A1
Application number	US-201514982734-A
Country	US
Kind code	A1
Filing date	Dec 29, 2015
Priority date	Jul 20, 2010
Publication date	Aug 25, 2016
Grant date	—

Abstract

Compositions for inducing or enhancing antigenicity of a target cell by modulating the nonsense mediated decay pathway in the target cell. The compositions comprise one or more cell binding ligands providing specificity and delivery of an oligonucleotide or other molecule to the target. These compositions have broad applicability in the treatment of many diseases.

First claim

What is claimed:

1 . A composition for inhibiting nonsense mediated decay (NMD) pathways in patients in vivo comprising at least one first domain which specifically binds to at least one tumor cell target or normal cell target in a tumor stroma and at least one second domain specific for a molecular component of nonsense mediated decay pathways, wherein the second domain comprises an antisense oligonucleotide molecule, peptides, proteins, nucleic acids, organic or inorganic molecules, which inhibit the nonsense mediated decay pathway.

2 . The composition of claim 1 , wherein the oligonucleotide molecule of the second domain, comprising at least one of a short interfering RNA (siRNA); a micro-interfering RNA (miRNA); antisense oligonucleotides; a small, temporal RNA (stRNA); a short, hairpin RNA (shRNA), or combinations thereof.

3 . The composition of claim 1 , wherein the oligonucleotide molecule of the second domain, inhibits function and/or expression of at least one factor associated with the NMD pathway comprising at least one of: RENT1, RENT2, eIF4A, UPF1, UPF2, UPF3B, RNPS1, Y14, MAGOH, NMD1, SMG, or combinations thereof.

4 . The composition of claim 1 , wherein the first domain specifically binds to tumor or normal cell targets in tumor stroma, comprising: vascular endothelial growth factor (VEGF), vascular endothelial growth factor receptor (VEGFR-2), Tie2; fibronectin, vitronectin, collagen, laminin, fibroblast antigens, fibroblast activation protein (FAP), glucose-regulated protein 78 (GRP78), stromal derived factor 1 (SDF-1), stromal derived factor 2 (SDF-2), MCP-1, MIP-1α, MIP-1β, RANTES, exotaxin IL-8, C3a, P-selectin, E-selectin, LFA-1, VLA-4, VLA-5, CD44, MMP activation, VEGF, EGF, PDGF, VCAM, ECAM, G-CSF, GM-CSF, SCF, EPO, tenascin, neurophilin, MAdCAM-1, neuropilin-1, α4 integrins, α5 integrins, or beta defensins 3 and 4.

5 . The composition of claim 4 , wherein the molecules comprising the first domain comprises: an aptamer, a multimer (aptamer), an antibody or fragments thereof, synthetic molecules, small molecules, peptides, peptides having a C-terminal arginine (CendR) motif or C-terminal lysine motif, glucose-regulated protein 78 (GRP78) binding peptides, integrin binding peptides, Pie42 peptides, or combinations thereof.

6 . The composition of claim 4 , wherein the molecules comprising the first domain comprise at least one peptide set forth as SEQ ID NOS: 1, 2, 3, 4, 5, 6, 7, 8, or combinations thereof.

7 . The composition of claim 1 , wherein the first and second domains further comprise one or more domains to promote intracellular delivery, cytoplasmic delivery, bioavailability, or combinations thereof.

8 . The composition of claim 5 , wherein the one or more domains, comprise at least one of: polylysine, polyarginine, Antennapedia-derived peptides, HIV derived tat peptide, a fusogenic peptide from influenza hemagglutinin protein, a 9mer Arg oligopeptide, peptide transporters, intracellular localization domain sequences, or combinations thereof.

9 . The composition of claim 5 , wherein the one or more domains promoting bioavailability comprising at least one of: cholesterol, polyethylene glycol, or combinations thereof.

10 . The composition of claim 1 , wherein the first domain is an aptamer specific for the target molecules and the second domain is an siRNA specific for an NMD target.

11 . The composition of claim 1 , wherein the at least one first domain are fused or linked to each other and/or with the second domain by at least one linker molecule.

12 . The composition of claim 11 , wherein said linker molecule comprising: nucleotide, non-nucleotide, or mixed nucleotide/non-nucleotide molecules.

13 . The composition of claim 11 , wherein the one or more linker molecules comprising about 2 nucleotides length up to about 50 nucleotides in length.

14 . The composition of claim 11 , wherein the non-nucleotide linker comprises abasic nucleotide, polyether, polyamine, polyamide, peptide, carbohydrate, lipid, polyhydrocarbon, polymeric compounds or combinations thereof, and having one or more monomeric units.

15 . A composition for inducing novel antigens in abnormal cells, comprising: a multi-domain molecule having at least one target specific domain and at least one domain, which modulates expression and function of molecules associated with nonsense mediated decay pathways.

16 . A method of inducing or enhancing immunogenicity of a target cell in vitro or in vivo and modulating an antigen specific immune response in patient comprising:
obtaining a composition comprising at least target binding molecule conjugated to at least one oligonucleotide molecule wherein the target binding ligand selectively binds to tumor cell or normal cell target ligands of tumor stroma and the oligonucleotide is specific for a molecule associated with at least one factor associated with a nonsense mediated decay pathway (NMD); administering the composition in a therapeutically effective amount to the patient; and, inducing or enhancing the immunogenicity of a target cell and modulating an antigen specific immune response in patient.

17 . The method of claim 16 , wherein the oligonucleotide molecule of the second domain comprising at least one of a short interfering RNA (siRNA); a micro-interfering RNA (miRNA); antisense oligonucleotide; a small, temporal RNA (stRNA); a short, hairpin RNA (shRNA), or combinations thereof.

18 . The method of claim 16 , wherein the oligonucleotide molecule of the second domain inhibits at least one factor associated with the NMD pathway comprising at least one of: RENT1, RENT2, UPF1, UPF2, UPF3B, RNPS1, Y14, MAGOH, NMD1 or SMG.

19 . The method of claim 16 , wherein target binding ligand selectively binds at least one of: vascular endothelial growth factor (VEGF), vascular endothelial growth factor receptor (VEGFR-2), Tie2; fibronectin, vitronectin, collagen, laminin, fibroblast antigens, fibroblast activation protein (FAP), glucose-regulated protein 78 (GRP78), stromal derived factor 1 (SDF-1), MCP-1, MIP-1 MIP-1β, RANTES, exotaxin IL-8, C3a, P-selectin, E-selectin, LFA-1, VLA-4, VLA-5, CD44, MMP activation, VEGF, EGF, PDGF, VCAM, ECAM, G-CSF, GM-CSF, SCF, EPO, tenascin, neuropilinMAdCAM-1, neuropilin-1, α4 integrins, α5 integrins, or beta defensins 3 and 4.

20 . The method of claim 16 , wherein the target binding ligand comprises at least one peptide having a C-terminal arginine (CendR) motif or C-terminal lysine motif, glucose-regulated protein 78 (GRP78) binding peptides, integrin binding peptides, or Pie42 peptides.

21 . The method of claim 16 , wherein the target binding ligand comprises at least one motif: RGD, R/KXXR/K, CX N+1 CX N+1 CX N+1 C motif, wherein X is a variable amino acid and n=0 to 50, variants, mutants or analogs thereof.

22 . The method of claim 16 , wherein the target binding ligands comprising the first domain comprise at least one peptide set forth as SEQ ID NOS: 1, 2, 3, 4, 5 or combinations thereof.

23 . The method of claim 16 , wherein target binding ligands comprise peptides which bind to tumor vasculature or tumor stroma are identified by phage display libraries or high-throughput screens.

24 . The method of claim 16 , wherein the target binding ligand is an aptamer.

25 . The method of claim 16 , further comprising administering an immune cell co-stimulatory agent comprising wherein the agent is specific for immune cell stim

Assignees

• Univ Miami

Inventors

• Gilboa Eli

Classifications

• C12N15/113 Primary

  Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)} · CPC title

• A61K47/48246

  Human Necessities · mapped topic

• A61K39/385 Primary

  Haptens or antigens, bound to carriers · CPC title

• A61K47/64

  Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65) · CPC title

• C12N2310/3513

  Protein; Peptide · CPC title